Interventional Cardiology Devices Market Development And Business Intelligence
Summary
- Major factors influencing the growth of the market.
- Leading players & Top Segments.
- Geographic Overview.
Market growth influenced due to following factors-
- Growth in the demand for interventional cardiology devices.
- Technological advancements in interventional cardiology devices.
- Improving healthcare infrastructure.
Global market size-
According to research report the interventional cardiology devices market is expected to reach $21.2 billion by 2025, at a CAGR of 8.9%
Leading Players-
The key players operating in the interventional cardiology devices market include Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), Terumo (Japan), Cordis (US), B. Braun (Germany), C.R. Bard (US), Biosensors (Singapore), and Biotronik (Germany).
Top Market Segments-
On the basis of type, the interventional cardiology devices market is categorized into angioplasty balloons, angioplasty stents, catheters, plaque modification devices, hemodynamic flow alteration devices, and other interventional cardiology devices.
The angioplasty stents market is further segmented into bare-metal stents, drug-eluting stents, and bioresorbable stents. The bioresorbable stents segment is estimated to register the highest growth during the forecast period. Growth in this segment can be attributed to the benefits associated with the use of these stents, such as the dissolvability feature which minimizes the risk of restenosis after the interventional procedure.
For Details, Download PDF Brochure Here
Geographic Overview -
The interventional cardiology devices market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). Asia Pacific is expected to register the highest growth due to the improving healthcare infrastructure, the heavy burden of cardiovascular diseases, rising healthcare expenditure, and growth in the demand for interventional cardiology devices.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.